Gelu-Simeon Moana, Duclos-Vallee Jean-Charles, Samuel Didier
Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, 94800, Villejuif, France.
DHU Hepatinov, 94800, Villejuif, France.
Hepatol Int. 2014 Sep;8 Suppl 2:481-5. doi: 10.1007/s12072-013-9508-2. Epub 2013 Dec 27.
Alcoholic hepatitis (AH) is a life-threatening disease, especially in its severe forms, with a 30-40 % mortality rate at 1 month in the absence of treatment. Severe forms are traditionally defined by Maddrey discriminant function >32. Until now, only corticosteroids have provided a significant benefit to survival in severe AH patients. Non-responders to corticosteroid therapy can be identified after 7 days of treatment when the Lille score is above 0.45, and this concerns about 40 % of patients with AH. With so few therapeutic alternatives for severe AH, the debate on liver transplantation (LT) has reopened. However, the latter indication for LT is facing several difficulties such as the 6-month abstinence rule ordinarily required for alcoholic diseases, risk of alcohol relapse and comprehensive fear of a drop in donations. Inversely, transplanted AH patients have a significantly improved survival, and an excess risk of alcohol relapse has not been demonstrated. Solutions can certainly be found in order to improve severe AH survival without causing a loss of opportunity for LT for other indications by good selection according to strict criteria.
酒精性肝炎(AH)是一种危及生命的疾病,尤其是重症形式,在未接受治疗的情况下,1个月时的死亡率为30%-40%。传统上,重症形式由Maddrey判别函数>32定义。到目前为止,只有皮质类固醇对重症AH患者的生存有显著益处。皮质类固醇治疗无反应者在治疗7天后当Lille评分高于0.45时可被识别,这涉及约40%的AH患者。由于重症AH的治疗选择如此之少,关于肝移植(LT)的争论再次展开。然而,LT的后一种指征面临着几个困难,如酒精性疾病通常要求的6个月戒酒规则、酒精复发风险以及对捐赠减少的全面担忧。相反,移植的AH患者生存有显著改善,且未证明有酒精复发的额外风险。通过根据严格标准进行良好选择,肯定可以找到解决方案,以提高重症AH的生存率,同时不会导致其他指征失去LT机会。